A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
暂无分享,去创建一个
A. Godwin | R. Mannel | K. Darcy | J. Hurteau | D. Benbrook | K. De Geest | M. Sill | P. Hanjani | D. Michelin | L. Usha